Benjamin Bitler
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 43 | 2025 | 487 | 12.890 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 10 | 2024 | 90 | 3.820 |
Why?
| Cystadenocarcinoma, Serous | 7 | 2024 | 68 | 3.250 |
Why?
| Claudin-4 | 4 | 2025 | 15 | 2.200 |
Why?
| Cell Line, Tumor | 37 | 2025 | 3178 | 2.100 |
Why?
| Genomic Instability | 2 | 2025 | 47 | 1.790 |
Why?
| Fallopian Tubes | 3 | 2024 | 30 | 1.770 |
Why?
| Drug Resistance, Neoplasm | 10 | 2024 | 749 | 1.670 |
Why?
| Nuclear Proteins | 10 | 2018 | 658 | 1.620 |
Why?
| Tumor Microenvironment | 10 | 2024 | 624 | 1.580 |
Why?
| Histone-Lysine N-Methyltransferase | 3 | 2024 | 125 | 1.560 |
Why?
| Transcription Factors | 13 | 2023 | 1635 | 1.510 |
Why?
| Phthalazines | 3 | 2019 | 41 | 1.400 |
Why?
| Gene Expression Regulation, Neoplastic | 20 | 2025 | 1349 | 1.320 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2024 | 812 | 1.270 |
Why?
| Piperazines | 3 | 2019 | 333 | 1.210 |
Why?
| Cellular Senescence | 7 | 2019 | 176 | 1.100 |
Why?
| Polycomb Repressive Complex 1 | 3 | 2024 | 47 | 1.090 |
Why?
| Antineoplastic Agents | 7 | 2024 | 2042 | 1.070 |
Why?
| BRCA2 Protein | 5 | 2024 | 53 | 0.960 |
Why?
| Autophagy | 2 | 2024 | 265 | 0.940 |
Why?
| Tryptophan Oxygenase | 2 | 2024 | 33 | 0.940 |
Why?
| Cell Proliferation | 11 | 2024 | 2345 | 0.910 |
Why?
| Neoplasms | 6 | 2023 | 2463 | 0.890 |
Why?
| Female | 58 | 2025 | 68268 | 0.880 |
Why?
| Histocompatibility Antigens | 2 | 2024 | 107 | 0.850 |
Why?
| Mucin-1 | 4 | 2012 | 20 | 0.830 |
Why?
| Ovary | 2 | 2022 | 210 | 0.800 |
Why?
| Mice | 28 | 2024 | 16620 | 0.790 |
Why?
| Breast Neoplasms | 6 | 2024 | 2135 | 0.790 |
Why?
| Protein-Arginine N-Methyltransferases | 2 | 2019 | 28 | 0.760 |
Why?
| DNA-Binding Proteins | 9 | 2020 | 1423 | 0.750 |
Why?
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2021 | 25 | 0.750 |
Why?
| Neoplasms, Glandular and Epithelial | 4 | 2018 | 35 | 0.740 |
Why?
| Mutation | 10 | 2022 | 3696 | 0.730 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2022 | 227 | 0.700 |
Why?
| Ascites | 1 | 2021 | 44 | 0.700 |
Why?
| Humans | 71 | 2025 | 128499 | 0.700 |
Why?
| Up-Regulation | 5 | 2020 | 823 | 0.700 |
Why?
| ErbB Receptors | 5 | 2024 | 603 | 0.700 |
Why?
| Genomics | 2 | 2024 | 715 | 0.690 |
Why?
| Animals | 39 | 2024 | 34647 | 0.680 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 61 | 0.680 |
Why?
| Epoxy Compounds | 1 | 2020 | 32 | 0.670 |
Why?
| Poly(ADP-ribose) Polymerases | 2 | 2019 | 88 | 0.660 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2020 | 45 | 0.660 |
Why?
| Rad51 Recombinase | 1 | 2019 | 13 | 0.660 |
Why?
| Metabolomics | 1 | 2024 | 602 | 0.650 |
Why?
| Indoles | 3 | 2019 | 372 | 0.630 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 381 | 0.630 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2024 | 842 | 0.610 |
Why?
| Wnt Signaling Pathway | 4 | 2021 | 166 | 0.600 |
Why?
| Signal Transduction | 10 | 2024 | 4825 | 0.600 |
Why?
| Proteomics | 1 | 2024 | 1018 | 0.580 |
Why?
| Neoadjuvant Therapy | 1 | 2020 | 382 | 0.580 |
Why?
| Membrane Proteins | 4 | 2019 | 1109 | 0.560 |
Why?
| Polycomb Repressive Complex 2 | 3 | 2015 | 63 | 0.560 |
Why?
| Pyridones | 2 | 2018 | 158 | 0.560 |
Why?
| Fatty Acids | 1 | 2020 | 417 | 0.540 |
Why?
| Wnt Proteins | 2 | 2021 | 126 | 0.520 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 6 | 2020 | 41 | 0.510 |
Why?
| Cell Nucleus | 3 | 2025 | 580 | 0.510 |
Why?
| Histone Deacetylases | 1 | 2017 | 210 | 0.490 |
Why?
| B7-H1 Antigen | 3 | 2024 | 190 | 0.480 |
Why?
| Endometrial Neoplasms | 3 | 2022 | 164 | 0.470 |
Why?
| Methyltransferases | 1 | 2015 | 70 | 0.450 |
Why?
| Molecular Targeted Therapy | 2 | 2021 | 385 | 0.430 |
Why?
| Anoikis | 3 | 2023 | 31 | 0.420 |
Why?
| Peptides | 3 | 2023 | 915 | 0.420 |
Why?
| Tryptophan | 2 | 2024 | 171 | 0.410 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 420 | 0.400 |
Why?
| Biological Assay | 1 | 2013 | 118 | 0.400 |
Why?
| Small Molecule Libraries | 1 | 2013 | 86 | 0.400 |
Why?
| Cell Survival | 3 | 2025 | 1076 | 0.400 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1562 | 0.400 |
Why?
| Azepines | 3 | 2017 | 88 | 0.400 |
Why?
| Biomarkers, Tumor | 5 | 2024 | 1179 | 0.380 |
Why?
| Gene Expression Profiling | 6 | 2023 | 1689 | 0.370 |
Why?
| Histones | 3 | 2023 | 588 | 0.370 |
Why?
| Triazoles | 3 | 2017 | 151 | 0.370 |
Why?
| Carcinogenesis | 3 | 2024 | 213 | 0.370 |
Why?
| Disease Progression | 8 | 2024 | 2604 | 0.360 |
Why?
| Inflammation | 2 | 2023 | 2666 | 0.350 |
Why?
| Cells | 1 | 2010 | 24 | 0.340 |
Why?
| Alternative Splicing | 2 | 2024 | 216 | 0.330 |
Why?
| Apoptosis | 6 | 2024 | 2437 | 0.330 |
Why?
| Mice, Transgenic | 6 | 2024 | 2069 | 0.330 |
Why?
| Neoplasm Invasiveness | 2 | 2024 | 478 | 0.330 |
Why?
| Neoplasm Grading | 5 | 2024 | 285 | 0.330 |
Why?
| Transcriptome | 3 | 2024 | 883 | 0.320 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2024 | 508 | 0.320 |
Why?
| BRCA1 Protein | 3 | 2021 | 65 | 0.300 |
Why?
| Carcinoma | 1 | 2010 | 215 | 0.300 |
Why?
| Fibroblasts | 1 | 2013 | 937 | 0.290 |
Why?
| RNA, Small Interfering | 5 | 2020 | 573 | 0.290 |
Why?
| Proto-Oncogene Proteins | 1 | 2011 | 633 | 0.290 |
Why?
| Piperidines | 2 | 2019 | 191 | 0.280 |
Why?
| DNA Repair | 3 | 2022 | 206 | 0.280 |
Why?
| Drug Delivery Systems | 1 | 2010 | 327 | 0.270 |
Why?
| Protein Kinase Inhibitors | 1 | 2013 | 880 | 0.270 |
Why?
| beta Catenin | 3 | 2022 | 218 | 0.270 |
Why?
| Peptide Fragments | 1 | 2010 | 688 | 0.260 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2018 | 209 | 0.250 |
Why?
| Oncogenes | 2 | 2019 | 111 | 0.250 |
Why?
| Imidazoles | 2 | 2024 | 229 | 0.250 |
Why?
| Prognosis | 3 | 2024 | 3780 | 0.240 |
Why?
| Cell Cycle | 3 | 2025 | 581 | 0.240 |
Why?
| Receptor, Interferon alpha-beta | 1 | 2024 | 33 | 0.230 |
Why?
| Micronuclei, Chromosome-Defective | 1 | 2024 | 5 | 0.230 |
Why?
| Amino Acid Transport System ASC | 1 | 2024 | 12 | 0.230 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 54 | 0.230 |
Why?
| Minor Histocompatibility Antigens | 1 | 2024 | 46 | 0.220 |
Why?
| Cytotoxicity, Immunologic | 1 | 2024 | 216 | 0.220 |
Why?
| Ligands | 2 | 2024 | 617 | 0.220 |
Why?
| Wnt4 Protein | 2 | 2024 | 19 | 0.220 |
Why?
| Endogenous Retroviruses | 1 | 2024 | 34 | 0.220 |
Why?
| Repressor Proteins | 2 | 2018 | 401 | 0.220 |
Why?
| DNA Transposable Elements | 1 | 2024 | 118 | 0.220 |
Why?
| Lysine | 2 | 2023 | 285 | 0.220 |
Why?
| Aldehyde Dehydrogenase | 2 | 2016 | 101 | 0.220 |
Why?
| Exons | 1 | 2024 | 339 | 0.210 |
Why?
| DNA Damage | 3 | 2022 | 370 | 0.210 |
Why?
| Polycomb-Group Proteins | 1 | 2023 | 28 | 0.210 |
Why?
| Kynurenine | 1 | 2024 | 105 | 0.210 |
Why?
| Activating Transcription Factor 6 | 1 | 2023 | 17 | 0.210 |
Why?
| Retinoblastoma-Binding Protein 2 | 1 | 2022 | 3 | 0.200 |
Why?
| Cell Movement | 3 | 2018 | 936 | 0.200 |
Why?
| Genital Neoplasms, Female | 1 | 2024 | 82 | 0.200 |
Why?
| Transcription Factor AP-1 | 1 | 2023 | 85 | 0.200 |
Why?
| Indazoles | 2 | 2021 | 65 | 0.200 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 210 | 0.200 |
Why?
| Cell Cycle Checkpoints | 4 | 2019 | 95 | 0.200 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.200 |
Why?
| Down-Regulation | 4 | 2022 | 632 | 0.190 |
Why?
| Single-Cell Analysis | 1 | 2024 | 276 | 0.190 |
Why?
| Tumor Cells, Cultured | 3 | 2019 | 930 | 0.190 |
Why?
| Tripartite Motif-Containing Protein 28 | 1 | 2021 | 14 | 0.190 |
Why?
| Carcinoma, Endometrioid | 1 | 2022 | 47 | 0.190 |
Why?
| Triple Negative Breast Neoplasms | 1 | 2024 | 197 | 0.190 |
Why?
| Granulosa Cells | 1 | 2021 | 32 | 0.180 |
Why?
| Killer Cells, Natural | 1 | 2024 | 427 | 0.180 |
Why?
| Antigen Presentation | 1 | 2022 | 205 | 0.180 |
Why?
| RNA Interference | 3 | 2019 | 441 | 0.180 |
Why?
| Ovarian Follicle | 1 | 2021 | 63 | 0.180 |
Why?
| Proteins | 2 | 2017 | 936 | 0.180 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1199 | 0.180 |
Why?
| Epigenomics | 1 | 2021 | 110 | 0.180 |
Why?
| Transfection | 3 | 2021 | 896 | 0.180 |
Why?
| Gene Knockdown Techniques | 2 | 2020 | 311 | 0.180 |
Why?
| Macrophages | 3 | 2024 | 1464 | 0.180 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2021 | 81 | 0.180 |
Why?
| Chromatin | 2 | 2016 | 479 | 0.170 |
Why?
| Cell Culture Techniques | 2 | 2020 | 345 | 0.170 |
Why?
| Enzyme Inhibitors | 1 | 2024 | 813 | 0.170 |
Why?
| Immunity | 2 | 2022 | 139 | 0.170 |
Why?
| Computational Biology | 1 | 2024 | 597 | 0.170 |
Why?
| Immunotherapy | 2 | 2021 | 589 | 0.170 |
Why?
| Germ-Line Mutation | 1 | 2021 | 138 | 0.170 |
Why?
| Interleukin-6 | 1 | 2024 | 715 | 0.170 |
Why?
| Wnt3A Protein | 1 | 2019 | 10 | 0.170 |
Why?
| Neoplasm Recurrence, Local | 2 | 2023 | 958 | 0.160 |
Why?
| Neoplasm Transplantation | 2 | 2011 | 257 | 0.160 |
Why?
| Transcription, Genetic | 4 | 2024 | 1404 | 0.160 |
Why?
| Acyltransferases | 1 | 2019 | 53 | 0.160 |
Why?
| Immunity, Innate | 2 | 2024 | 803 | 0.160 |
Why?
| Gene Frequency | 1 | 2021 | 504 | 0.160 |
Why?
| Receptors, Adiponectin | 1 | 2019 | 19 | 0.160 |
Why?
| Diagnostic Imaging | 1 | 2022 | 332 | 0.160 |
Why?
| E2F Transcription Factors | 1 | 2019 | 59 | 0.160 |
Why?
| Sequence Analysis, DNA | 2 | 2021 | 775 | 0.160 |
Why?
| Amino Acid Sequence | 4 | 2015 | 2044 | 0.160 |
Why?
| Image Processing, Computer-Assisted | 1 | 2023 | 737 | 0.160 |
Why?
| Isocitrate Dehydrogenase | 1 | 2019 | 52 | 0.160 |
Why?
| NF-kappa B | 1 | 2023 | 650 | 0.160 |
Why?
| Survival Rate | 2 | 2020 | 1871 | 0.150 |
Why?
| Heterografts | 1 | 2019 | 129 | 0.150 |
Why?
| CA-125 Antigen | 1 | 2018 | 15 | 0.150 |
Why?
| Protein Processing, Post-Translational | 2 | 2021 | 453 | 0.150 |
Why?
| Chloride Channels | 1 | 2018 | 38 | 0.150 |
Why?
| RNA Splicing Factors | 1 | 2018 | 52 | 0.150 |
Why?
| Drug Repositioning | 1 | 2018 | 25 | 0.150 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 115 | 0.140 |
Why?
| Genetic Testing | 1 | 2021 | 428 | 0.140 |
Why?
| Cell Cycle Proteins | 4 | 2017 | 581 | 0.140 |
Why?
| Paclitaxel | 1 | 2019 | 214 | 0.140 |
Why?
| Histone Deacetylase 6 | 1 | 2017 | 17 | 0.140 |
Why?
| Mice, SCID | 3 | 2018 | 350 | 0.140 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 185 | 0.140 |
Why?
| Uterine Cervical Neoplasms | 1 | 2020 | 232 | 0.140 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1201 | 0.140 |
Why?
| Sequence Analysis, RNA | 1 | 2019 | 428 | 0.140 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 81 | 0.140 |
Why?
| Claudins | 1 | 2017 | 25 | 0.140 |
Why?
| Heterochromatin | 2 | 2016 | 41 | 0.140 |
Why?
| HMGB2 Protein | 1 | 2016 | 5 | 0.130 |
Why?
| Secretory Pathway | 1 | 2016 | 6 | 0.130 |
Why?
| Mevalonic Acid | 1 | 2016 | 11 | 0.130 |
Why?
| Colorectal Neoplasms | 1 | 2024 | 751 | 0.130 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2016 | 14 | 0.130 |
Why?
| Tight Junctions | 1 | 2017 | 74 | 0.130 |
Why?
| Acetylation | 1 | 2017 | 246 | 0.130 |
Why?
| Genetics, Population | 2 | 2008 | 200 | 0.130 |
Why?
| Mass Spectrometry | 1 | 2019 | 663 | 0.130 |
Why?
| Oxidation-Reduction | 1 | 2020 | 1003 | 0.130 |
Why?
| Mammary Glands, Animal | 1 | 2017 | 124 | 0.130 |
Why?
| Tumor Burden | 1 | 2017 | 284 | 0.130 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 433 | 0.130 |
Why?
| RNA, Long Noncoding | 1 | 2018 | 178 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 283 | 0.130 |
Why?
| Mice, Nude | 2 | 2015 | 678 | 0.130 |
Why?
| Endopeptidases | 1 | 2015 | 85 | 0.120 |
Why?
| Biomarkers | 2 | 2024 | 3893 | 0.120 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 357 | 0.120 |
Why?
| Genetic Loci | 1 | 2016 | 275 | 0.120 |
Why?
| Oxidative Stress | 1 | 2021 | 1191 | 0.120 |
Why?
| T-Lymphocytes | 1 | 2022 | 1923 | 0.110 |
Why?
| Epithelial Cells | 2 | 2017 | 1043 | 0.110 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1046 | 0.110 |
Why?
| Tomography, X-Ray Computed | 1 | 2023 | 2517 | 0.110 |
Why?
| Oncogene Protein p21(ras) | 1 | 2013 | 16 | 0.110 |
Why?
| Pyrimidine Nucleotides | 1 | 2013 | 3 | 0.110 |
Why?
| Purine Nucleotides | 1 | 2013 | 12 | 0.110 |
Why?
| beta-Galactosidase | 1 | 2013 | 76 | 0.100 |
Why?
| CCAAT-Binding Factor | 1 | 2013 | 4 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 1 | 2017 | 1951 | 0.100 |
Why?
| Primary Cell Culture | 1 | 2013 | 157 | 0.100 |
Why?
| Genes, Reporter | 1 | 2013 | 266 | 0.100 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2017 | 819 | 0.100 |
Why?
| Proteome | 1 | 2016 | 432 | 0.100 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 74 | 0.100 |
Why?
| RNA Helicases | 1 | 2011 | 23 | 0.090 |
Why?
| Genes, ras | 1 | 2011 | 97 | 0.090 |
Why?
| Wnt-5a Protein | 1 | 2011 | 21 | 0.090 |
Why?
| Follow-Up Studies | 1 | 2020 | 4874 | 0.090 |
Why?
| Interferons | 2 | 2024 | 192 | 0.090 |
Why?
| Golgi Apparatus | 1 | 2011 | 98 | 0.090 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2822 | 0.090 |
Why?
| Gene Flow | 2 | 2008 | 76 | 0.090 |
Why?
| Cell Line | 4 | 2021 | 2741 | 0.090 |
Why?
| Models, Biological | 3 | 2019 | 1698 | 0.090 |
Why?
| AMP-Activated Protein Kinases | 2 | 2024 | 189 | 0.090 |
Why?
| Endosomes | 1 | 2011 | 126 | 0.090 |
Why?
| Cyclin D1 | 1 | 2010 | 63 | 0.080 |
Why?
| Gene Expression Regulation | 3 | 2016 | 2516 | 0.080 |
Why?
| Active Transport, Cell Nucleus | 1 | 2010 | 112 | 0.080 |
Why?
| Lung Neoplasms | 1 | 2022 | 2329 | 0.080 |
Why?
| Aged, 80 and over | 1 | 2021 | 7057 | 0.080 |
Why?
| Arachnida | 1 | 2008 | 5 | 0.080 |
Why?
| Cloning, Molecular | 1 | 2010 | 522 | 0.080 |
Why?
| Caenorhabditis elegans Proteins | 1 | 2011 | 191 | 0.080 |
Why?
| Protein Binding | 2 | 2016 | 2110 | 0.080 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2009 | 66 | 0.080 |
Why?
| HEK293 Cells | 2 | 2024 | 683 | 0.070 |
Why?
| Cytoplasm | 1 | 2009 | 258 | 0.070 |
Why?
| Middle Aged | 4 | 2024 | 30923 | 0.070 |
Why?
| Prostatic Neoplasms | 1 | 2015 | 1016 | 0.070 |
Why?
| Immunohistochemistry | 2 | 2022 | 1668 | 0.070 |
Why?
| Aged | 3 | 2024 | 21976 | 0.070 |
Why?
| Neoplasm Metastasis | 3 | 2020 | 610 | 0.070 |
Why?
| Neoplasm Staging | 1 | 2011 | 1292 | 0.070 |
Why?
| Trans-Activators | 1 | 2010 | 384 | 0.070 |
Why?
| Mammary Neoplasms, Animal | 1 | 2007 | 30 | 0.070 |
Why?
| Transforming Growth Factor alpha | 1 | 2007 | 55 | 0.070 |
Why?
| Cactaceae | 1 | 2006 | 5 | 0.070 |
Why?
| Triatoma | 1 | 2006 | 5 | 0.070 |
Why?
| Mice, Inbred NOD | 2 | 2018 | 586 | 0.060 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 837 | 0.060 |
Why?
| Phylogeny | 2 | 2008 | 849 | 0.060 |
Why?
| Drosophila | 1 | 2006 | 142 | 0.060 |
Why?
| Genetic Variation | 2 | 2008 | 935 | 0.060 |
Why?
| Epigenesis, Genetic | 2 | 2020 | 614 | 0.060 |
Why?
| Evolution, Molecular | 1 | 2008 | 465 | 0.060 |
Why?
| Retinal Dehydrogenase | 2 | 2016 | 30 | 0.060 |
Why?
| Protein Transport | 2 | 2019 | 421 | 0.060 |
Why?
| Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.060 |
Why?
| Signal-To-Noise Ratio | 1 | 2023 | 68 | 0.050 |
Why?
| Cytokine TWEAK | 1 | 2023 | 1 | 0.050 |
Why?
| Transcription Factor RelB | 1 | 2023 | 3 | 0.050 |
Why?
| TWEAK Receptor | 1 | 2023 | 5 | 0.050 |
Why?
| Tumor Necrosis Factors | 1 | 2023 | 10 | 0.050 |
Why?
| Muscular Atrophy | 1 | 2023 | 79 | 0.050 |
Why?
| Protein Isoforms | 1 | 2024 | 378 | 0.050 |
Why?
| Enhancer Elements, Genetic | 1 | 2024 | 177 | 0.050 |
Why?
| Artifacts | 1 | 2023 | 123 | 0.050 |
Why?
| Cachexia | 1 | 2023 | 60 | 0.050 |
Why?
| Homologous Recombination | 1 | 2022 | 23 | 0.050 |
Why?
| Recombinational DNA Repair | 1 | 2022 | 13 | 0.050 |
Why?
| Carboplatin | 1 | 2023 | 140 | 0.050 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 160 | 0.050 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 757 | 0.050 |
Why?
| Gene Regulatory Networks | 1 | 2024 | 281 | 0.050 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2021 | 26 | 0.050 |
Why?
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 31 | 0.050 |
Why?
| Open Reading Frames | 1 | 2021 | 115 | 0.040 |
Why?
| Cluster Analysis | 1 | 2022 | 479 | 0.040 |
Why?
| Mice, Inbred C57BL | 3 | 2018 | 5281 | 0.040 |
Why?
| Tumor Escape | 1 | 2020 | 38 | 0.040 |
Why?
| Cell Division | 1 | 2021 | 777 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2019 | 108 | 0.040 |
Why?
| Paracrine Communication | 1 | 2019 | 60 | 0.040 |
Why?
| Chromatin Assembly and Disassembly | 1 | 2020 | 101 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2021 | 332 | 0.040 |
Why?
| Protein Biosynthesis | 1 | 2021 | 398 | 0.040 |
Why?
| Computer Simulation | 1 | 2023 | 939 | 0.040 |
Why?
| Coculture Techniques | 1 | 2019 | 226 | 0.040 |
Why?
| Blotting, Western | 2 | 2011 | 1170 | 0.040 |
Why?
| Immunophenotyping | 1 | 2020 | 309 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 116 | 0.040 |
Why?
| Stem Cells | 1 | 2023 | 578 | 0.040 |
Why?
| Flow Cytometry | 1 | 2022 | 1142 | 0.040 |
Why?
| Survival Analysis | 1 | 2021 | 1265 | 0.040 |
Why?
| Mitosis | 1 | 2019 | 178 | 0.040 |
Why?
| Gene Amplification | 1 | 2018 | 104 | 0.040 |
Why?
| Recurrence | 1 | 2021 | 1004 | 0.040 |
Why?
| Aniline Compounds | 1 | 2018 | 96 | 0.040 |
Why?
| Desert Climate | 2 | 2008 | 14 | 0.040 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2019 | 205 | 0.040 |
Why?
| Arizona | 2 | 2008 | 78 | 0.040 |
Why?
| Pyridines | 1 | 2021 | 474 | 0.040 |
Why?
| Disease Management | 1 | 2021 | 584 | 0.030 |
Why?
| Mexico | 2 | 2008 | 190 | 0.030 |
Why?
| DNA Helicases | 1 | 2018 | 149 | 0.030 |
Why?
| Drug Synergism | 1 | 2017 | 357 | 0.030 |
Why?
| Phosphorylation | 1 | 2021 | 1686 | 0.030 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2018 | 201 | 0.030 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2021 | 1187 | 0.030 |
Why?
| DNA, Mitochondrial | 2 | 2008 | 190 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2016 | 108 | 0.030 |
Why?
| Algorithms | 1 | 2023 | 1614 | 0.030 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 168 | 0.030 |
Why?
| Sumoylation | 1 | 2015 | 16 | 0.030 |
Why?
| Lactation | 1 | 2017 | 170 | 0.030 |
Why?
| Metabolic Networks and Pathways | 1 | 2016 | 175 | 0.030 |
Why?
| Proteolysis | 1 | 2015 | 162 | 0.030 |
Why?
| Models, Genetic | 2 | 2008 | 593 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2016 | 381 | 0.030 |
Why?
| Gene Silencing | 1 | 2015 | 183 | 0.030 |
Why?
| Sulfonamides | 1 | 2018 | 495 | 0.030 |
Why?
| Cisplatin | 1 | 2016 | 298 | 0.030 |
Why?
| Protein-Tyrosine Kinases | 1 | 2017 | 431 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2017 | 1227 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2016 | 456 | 0.030 |
Why?
| Muscle, Skeletal | 1 | 2023 | 1624 | 0.030 |
Why?
| E2F7 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
| Ribonucleoside Diphosphate Reductase | 1 | 2013 | 4 | 0.030 |
Why?
| Nucleosides | 1 | 2013 | 26 | 0.030 |
Why?
| Melanoma | 1 | 2020 | 724 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 52 | 0.030 |
Why?
| Epidermal Growth Factor | 1 | 2012 | 170 | 0.020 |
Why?
| ras Proteins | 1 | 2013 | 144 | 0.020 |
Why?
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 6 | 0.020 |
Why?
| Time Factors | 2 | 2016 | 6506 | 0.020 |
Why?
| Mice, Knockout | 1 | 2018 | 2765 | 0.020 |
Why?
| Genes, BRCA1 | 1 | 2011 | 32 | 0.020 |
Why?
| Sorting Nexins | 1 | 2011 | 10 | 0.020 |
Why?
| Two-Hybrid System Techniques | 1 | 2011 | 56 | 0.020 |
Why?
| Chromatin Immunoprecipitation | 1 | 2011 | 131 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2011 | 157 | 0.020 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 212 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 324 | 0.020 |
Why?
| Endocytosis | 1 | 2011 | 161 | 0.020 |
Why?
| Protein Folding | 1 | 2011 | 266 | 0.020 |
Why?
| HeLa Cells | 1 | 2011 | 606 | 0.020 |
Why?
| Cell Transformation, Neoplastic | 1 | 2011 | 325 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 2011 | 636 | 0.020 |
Why?
| Geography | 1 | 2008 | 188 | 0.020 |
Why?
| Phenotype | 1 | 2016 | 3051 | 0.020 |
Why?
| Population Dynamics | 1 | 2008 | 136 | 0.020 |
Why?
| Caenorhabditis elegans | 1 | 2011 | 291 | 0.020 |
Why?
| Cells, Cultured | 1 | 2015 | 4017 | 0.020 |
Why?
| Haplotypes | 1 | 2008 | 471 | 0.020 |
Why?
| Genes, Insect | 1 | 2006 | 21 | 0.020 |
Why?
| Cytochromes b | 1 | 2006 | 10 | 0.020 |
Why?
| Insect Vectors | 1 | 2006 | 27 | 0.020 |
Why?
| Electron Transport Complex IV | 1 | 2006 | 57 | 0.020 |
Why?
| Lymphoma | 1 | 2007 | 195 | 0.020 |
Why?
| Chagas Disease | 1 | 2006 | 35 | 0.020 |
Why?
| Host-Parasite Interactions | 1 | 2006 | 103 | 0.020 |
Why?
| Pregnancy | 1 | 2017 | 6373 | 0.010 |
Why?
| Bayes Theorem | 1 | 2006 | 373 | 0.010 |
Why?
| RNA, Messenger | 1 | 2011 | 2679 | 0.010 |
Why?
| Firefly Luciferin | 1 | 1957 | 1 | 0.010 |
Why?
| Diptera | 1 | 1957 | 29 | 0.010 |
Why?
| Luciferases | 1 | 1957 | 147 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2007 | 3947 | 0.010 |
Why?
| Male | 1 | 2015 | 63045 | 0.000 |
Why?
|
|
Bitler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|